Cisapride (R 51619): Next-Generation Insights for Cardiac and Motility Research

Introduction

Cisapride (R 51619) has emerged as a cornerstone compound in cardiac electrophysiology research, recognized for its dual role as a nonselective 5-HT4 receptor agonist and a potent inhibitor of the hERG potassium channel. While existing literature highlights its utility in predictive safety and deep learning-enabled in vitro modeling, this article offers a focused exploration of Cisapride (R 51619) as a molecular probe for dissecting ion channel dynamics, gastrointestinal motility, and advanced phenotypic screening. By bridging technical product features with next-generation experimental strategies, we provide a distinctive blueprint for researchers aiming to unravel complex signaling pathways and arrhythmia mechanisms in both cardiac and enteric systems.

Mechanism of Action of Cisapride (R 51619)

5-HT4 Receptor Agonism: Beyond Gastrointestinal Motility

Cisapride is chemically defined as 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide (molecular weight 465.95), and functions as a nonselective 5-HT4 receptor agonist. The 5-HT4 receptor, a G protein-coupled receptor (GPCR), is expressed in both neuronal and cardiac tissues, where it modulates cyclic adenosine monophosphate (cAMP) production and downstream signaling. In the gastrointestinal tract, this mechanism accelerates motility by enhancing acetylcholine release from enteric neurons. Accordingly, Cisapride has been a key tool in gastrointestinal motility studies, providing a pharmacological means to probe peristaltic function and neurotransmitter dynamics.

hERG Potassium Channel Inhibition: Implications for Cardiac Electrophysiology

In cardiac myocytes, Cisapride’s potent inhibition of the human ether-à-go-go-related gene (hERG) potassium channel disrupts the rapid delayed rectifier potassium current (I_Kr). This prolongs the cardiac action potential and can induce arrhythmogenic phenotypes, such as long QT syndrome—a critical consideration in cardiac arrhythmia research. The dual activity of Cisapride thus uniquely positions it for studies requiring both receptor-based signaling interrogation and precise modulation of ion channel function.

Product Profile: Chemical and Handling Considerations

Supplied by APExBIO at an exceptional purity of 99.70%, Cisapride (R 51619) is provided as a solid, with solubility confirmed at ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol. It is insoluble in water—a factor critical in experimental design for in vitro and ex vivo assays. The compound should be stored at -20°C for stability, and long-term storage of solution is not recommended due to potential degradation. Each lot includes comprehensive QC data (HPLC, NMR, MSDS), ensuring reproducibility and traceability for rigorous research applications.

Distinctive Applications in Cardiac Electrophysiology Research

Dissecting Arrhythmia Mechanisms with hERG Channel Inhibitors

The inhibition of hERG channels by Cisapride enables detailed modeling of acquired and congenital arrhythmias in human-derived cardiomyocytes. By manipulating the I_Kr current, researchers can recapitulate clinically relevant electrophysiological abnormalities, test the proarrhythmic potential of new drug candidates, and validate rescue strategies in vitro. Unlike other hERG blockers, Cisapride’s concurrent 5-HT4 receptor activity allows for sophisticated studies of the interplay between neurotransmitter signaling and cardiac repolarization.

Leveraging iPSC-Derived Cardiomyocytes and Deep Learning

Recent advances in stem cell technology have enabled the generation of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), which more accurately recapitulate human cardiac physiology compared to immortalized cell lines. A seminal study by Grafton et al. (2021) demonstrated the power of combining iPSC-CMs with high-content screening and deep learning to rapidly identify drug-induced cardiotoxicity. In this context, Cisapride serves as a benchmark hERG channel inhibitor, generating robust arrhythmogenic phenotypes that can be detected and quantified by machine learning algorithms. This approach not only accelerates early-stage drug discovery but also improves translational relevance and predictive accuracy.

Innovations in Gastrointestinal Motility Studies

While much attention has focused on Cisapride’s cardiac effects, its 5-HT4 receptor agonism continues to inform studies of enteric neurobiology and gut motility. By activating 5-HT4-mediated pathways, Cisapride facilitates the study of neurogastroenterology, smooth muscle physiology, and the development of prokinetic therapies. Its dual role enables cross-system investigations—probing, for instance, how gastrointestinal and cardiac systems interact via shared neurotransmitter and ion channel networks.

Comparative Analysis with Alternative Probes and Methodologies

Most existing articles, such as "Cisapride (R 51619): Powering Cardiac Electrophysiology Research", emphasize the compound’s status as a gold-standard hERG inhibitor for high-content cardiotoxicity assays. Our article builds upon this by contextualizing Cisapride within the broader spectrum of 5-HT4 agonists and hERG blockers, such as dofetilide, sotalol, and prucalopride. Unlike highly selective probes, Cisapride’s dual activity supports multidimensional experimental designs, facilitating comparisons between receptor-driven and direct ion channel effects.

Furthermore, while previous content such as "Cisapride (R 51619): Precision in Cardiac Electrophysiology" primarily addresses translational workflows and deep learning integration, this article provides a deeper mechanistic analysis—detailing how Cisapride’s nonselective action can be exploited to dissect crosstalk between electrophysiological and neurotransmitter pathways in both cardiac and gastrointestinal models.

Advanced Applications: Integrating Cisapride in Phenotypic Screening and Systems Biology

Combining Chemical Genetics with High-Content Imaging

Cisapride’s defined molecular activity makes it an ideal candidate for chemical genetics screens, wherein genetically engineered iPSC-CMs or neuronal cells are perturbed with small molecules to elucidate pathway dependencies or genotype-specific drug responses. High-content imaging, coupled with advanced analytics, enables single-cell resolution of phenotypic changes—such as action potential duration, arrhythmic beating patterns, or receptor desensitization.

Systems Pharmacology and Predictive Toxicology

By leveraging Cisapride in conjunction with multi-parametric readouts—electrophysiological recordings, transcriptomics, and deep phenotyping—researchers can construct systems-level maps of drug-induced perturbations. This aligns with the paradigm shift described by Grafton et al., where early de-risking of drug candidates is achieved through scalable, human-relevant models. Notably, the integration of deep learning allows for unbiased detection of subtle cardiotoxic or proarrhythmic signatures, transforming the assessment of drug safety and efficacy.

Practical Considerations: Experimental Design and Data Interpretation

• Handling and Storage: Prepare fresh DMSO or ethanol stock solutions of Cisapride immediately prior to use to maintain compound integrity. Avoid water-based solvents due to insolubility.
• Concentration Selection: Titrate concentrations based on desired inhibition of hERG or activation of 5-HT4, with reference to published IC₅₀/EC₅₀ values for your target system.
• Controls: Incorporate both positive (e.g., other hERG inhibitors) and negative controls to validate assay specificity and sensitivity.
• Phenotypic Readouts: Use a combination of electrophysiological, imaging, and transcriptomic endpoints to capture the full range of Cisapride’s effects.

Navigating Nomenclature: Avoiding Confusion in Literature Searches

The compound is variably referred to as cisaprode, cisparide, or cispride in different databases and publications. When searching for protocols, safety data, or literature, consider all these synonyms to ensure comprehensive coverage. However, for consistency, the IUPAC designation and APExBIO’s catalog entry for Cisapride (R 51619) should be used in formal documentation.

Conclusion and Future Outlook

Cisapride (R 51619) stands as a uniquely versatile molecular probe—bridging the domains of cardiac electrophysiology, 5-HT4 receptor signaling, and gastrointestinal motility research. Its dual activity profile unlocks experimental possibilities not afforded by more selective agents, while its compatibility with iPSC-CMs and advanced phenotypic screening workflows sets a new standard for translational research. By integrating insights from deep learning-enabled cardiotoxicity assays (Grafton et al., 2021) and leveraging high-purity, rigorously characterized materials from APExBIO, scientists can advance the frontiers of safety pharmacology, drug discovery, and systems biology.

For those seeking further perspectives on predictive safety screening and translational workflows, see our comparative analysis with "Cisapride (R 51619): Advancing Predictive Cardiac Electrophysiology". While that article addresses the integration of regulatory and workflow considerations, our present article delves deeper into the mechanistic and multi-systemic applications of Cisapride, offering a roadmap for next-generation research.

For detailed product specifications or to order, visit the APExBIO Cisapride (R 51619) product page.